[Current status of estrogen-progestational contraception].
The final decade of the century confirms the importance of latest generation progestogens in terms of decreased risks associated with the use of doses of ethinyl estradiol of 50 gamma or more, equally effective in contraception of this type. These new combination very considerably limit the untoward effects seen in the past regarding carbohydrate and lipid metabolism, as well as cardiovascular disease. Concerning carcinogenesis, the long term protective effect against carcinomas of the endometrium and ovary is now accepted, while studies of breast cancer are not unanimous in their condemnation, the same applying to the risk of hepatocarcinoma. Regulation of cycles is satisfactory and the vaginal flora little affected. Moderate and stable fibroids seem to be well controlled, the same applying to mucosal hyperplasia. Pregnancy, particularly rare, is not influenced unfavourably and the effect on lactation appears to be nil. Provided that regular monitoring is ensured and contraindications are respected, age does not appear to be an absolute limiting factor to its use but the risk of concomitant smoking remains.
Service de Gynécologie-Obstétrique II, CHU Dupuytren, Limoges.
J L
JL
Tabaste
F
F
Lesourd-Pontonnier
D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology / Q000627:therapeutic use*; D003278:Contraceptives, Oral, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects
D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal
Le point actuel sur la contraception estroprogestative.